Ultima-CJC no DAC 5mg

MANUFACTURER Ultima Pharmaceuticals - USA
WAREHOUSE USA Warehouse 5
SUBSTANCE GHRH Peptide

For your security, all products are shipped discreetly without branding.

Introducing CJC-1295, a powerful synthetic analog of growth hormone-releasing hormone (GHRH) that comprises 30 essential amino acids. Renowned for its ability to significantly enhance the secretion of growth hormone and IGF-1, CJC-1295 maintains the natural pulsatility of GH release, making it a top choice for those seeking to optimize their growth hormone levels.

This peptide is often combined with Ipamorelin to maximize its specificity as a GHRH. While both peptides promote growth hormone increases, CJC-1295 stands out by not triggering appetite or elevating cortisol, acetylcholine, prolactin, or aldosterone, as seen with some alternatives. Its well-tolerated nature makes it an excellent complement to Ipamorelin.

Target Gland: Pituitary

Key Benefits of CJC-1295 include:

• Enhanced growth hormone and IGF-1 secretion without raising prolactin levels
• Increased body weight and height through improved protein synthesis
• Significant muscle mass gains
• Improved bone density
• Strengthened immune response
• Boosted cognitive function and memory retention
• Increased collagen production
• Effective fat loss
• Enhanced cellular repair and regeneration

Additionally, CJC-1295 promotes deep, restorative slow-wave sleep, essential for muscle growth and memory consolidation.

There are two variants of CJC-1295:

The first variant, GHRH, is produced in the hypothalamus and releases growth hormone in a pulsatile fashion from the pituitary. However, it has a very short half-life of just a few minutes, leading to rapid elimination from the body.

The active segment of GHRH consists of the initial 29 amino acids and is available commercially as Sermorelin, which has been modified to extend its half-life to approximately 30 minutes. This is known as CJC-1295. Further modifications, including the addition of DAC (Drug Affinity Complex), prolong its half-life to around 8 days, resulting in the variant CJC-1295 + DAC. Alternatively, CJC-1295 can be formulated in a non-DAC form, which creates a more natural growth hormone spike each night.

This extended half-life allows for just one or two injections per week; however, the sustained levels may provide a continuous stimulus for GH release from the pituitary via the GHRH receptor, which may not be physiological. This could potentially reduce the amplitude of GH pulses and subsequently decrease stimulation of GH-responsive tissues.

Safety Considerations:

It is recommended to take 'hormone holidays' every three to six months while using long-acting CJC forms, allowing the pituitary to recover. During these breaks, Sermorelin can be used as an alternative to CJC-1295 + DAC.

Implementing these 'hormone holidays' may also help mitigate the risk of developing GH resistance, which could arise from the formation of antibodies that bind to and deactivate GH or a reduction of GH receptors on tissues (down-regulation). While these concerns are theoretical, long-term studies have not confirmed them.

Possible side effects of CJC-1295 may include injection site reactions (irritation, redness, swelling, pain, itching), headaches, diarrhea, flushing (vasodilation), temporary low blood pressure, nausea, and abdominal discomfort.